Figure 4.

Svg3 elicited potent IFN-I responses in human monocytes and ex vivo human tumor tissues

(A) Svg3 elicited potent IFN-I responses that outperformed STING agonist 2′3′-cGAMP in human THP-I monocytes. Marked on the right of treatment legends are EC₅₀ values. Svg3 and 2′3′-cGAMP were transfected using Lipofectamine 2000. (B) Relative gene expression showed that Svg3 elicited IFN-I responses in ex vivo head and neck squamous cell carcinoma tissues. Liposomal Svg3 (Svg3: 0.1 nmol) were injected directly into cultured tumor tissues (cohort study, n = 3) cultured in medium (1 mL). Twenty-four hours later, the mRNA levels of related cytokines were determined by qPCR. Data: mean ± SD. p values were determined by t test. ns, not significant; p > 0.05, ∗p < 0.05.